gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Mdm2 p53 binding protein homolog

mdm2, HDM2
This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: p53, CAN, V1a, HAD, Ubiquitin
Papers using mdm2 antibodies
Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy
Musaro Antonio, In PLoS ONE, 2005
... Signalling, USA), monoclonal anti mono and poly ubiquitination, Ab clone FK-1 (Enzo Lifescience, USA), monoclonal anti-MDM2 (AbCam, USA) ...
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1
Durden Donald L. et al., In Cancer Chemotherapy and Pharmacology, 2005
... Antibodies specific for Akt, phospho-S473-Akt, p53, MDM2, phospho-S166-MDM2 and PARP were obtained from Cell Signaling Technology (Danvers, MA) and ...
p14ARF gene alterations in human hepatocellular carcinoma
Guan Xin-yuan, In PLoS ONE, 2003
... (FL), mouse anti-Myc (9E10), rabbit anti-Myc (A-14), mouse anti-p53 (DO-1), mouse anti-phospho-p53 (S15) and rabbit anti-MDM2 (C-18) were purchased from Santa Cruz Biotechnology.
Stabilization and activation of p53 by the coactivator protein TAFII31
Keith W Nicol et al., In BMC Cancer, 2000
... Antibodies to Sp1, TFIIB and mdm2 were purchased from Santa Cruz Biotechnology Inc ...
CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner
Martínez-A. Carlos et al., In The Journal of Experimental Medicine, 1995
... deoxycholate, 1% NP-40) were analyzed by Western blot with anti-p53 (Oncogene Research Products), anti-p21 and anti-Mdm2 (Santa Cruz Biotechnology, Inc.), anti-p38 and anti–phospho-p38 ...
more suppliers
Papers on mdm2
Protein-protein interactions among signaling pathways may become new therapeutic targets in liver cancer (Review).
Sun et al., Shanghai, China. In Oncol Rep, Feb 2016
For instance, in the PI3K/AKT signaling pathway, protein AKT binds with a number of proteins such as mTOR, FOXO1 and MDM2 to play an oncogenic role in liver cancer.
Whole exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
Gomez-Brouchet et al., Toulouse, France. In Ann Oncol, Feb 2016
We also observed that a dedifferentiated osteosarcoma harbouring MDM2 amplification did not carry any other mutations.
Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer.
Goode et al., Rochester, United States. In Oncology, Feb 2016
In univariate analyses, overexpression of TFF3, MDM2, and p53 were associated with improved recurrence-free survival.
The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα.
He et al., Hangzhou, China. In Oncogene, Feb 2016
In this study, we discover that murine double minute-2 (MDM2) acts as an E3 ubiquitin ligase to target RARα for degradation.
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.
Coleman et al., New York City, United States. In J Urol, Feb 2016
RESULTS: Of the 24 most commonly altered genes within 9 pathways, TP53/MDM2 alterations and FGFR3 mutations were the only two alterations uniformly associated with high-grade, advanced stage, non-organ-confined disease, recurrence-free survival, and cancer-specific survival.
Cellular functions of programmed cell death 5.
Chen et al., Beijing, China. In Biochim Biophys Acta, Feb 2016
PDCD5 regulates the activities of TIP60, HDAC3, MDM2 and TP53 transcription factors.
Giant Scrotal Fibrolipoma.
Sountoulides et al., Thessaloníki, Greece. In Rare Tumors, Jan 2016
On immunohistochemistry, MDM2 and CDK4 were not expressed.
Peptide-based inhibitors of protein-protein interactions.
Berlicki et al., Wrocław, Poland. In Bioorg Med Chem Lett, Jan 2016
Importantly, numerous specific protein-protein interactions (e.g., p53-HDM2 and Bcl-2-BH3 domains) were found to be involved in the development of several diseases, including various types of cancer.
DNA replication stress as a hallmark of cancer.
Halazonetis et al., Genève, Switzerland. In Annu Rev Pathol, 2014
The sustained proliferation hallmark can be explained by mutations in oncogenes and tumor suppressors that regulate cell growth, whereas the escape from apoptosis hallmark can be explained by mutations in the TP53, ATM, or MDM2 genes.
L-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.
Kenner et al., Vienna, Austria. In Swiss Med Wkly, 2014
The identification of the alternative reading frame protein (ARF) / murine double minute protein (MDM2) / p53 tumour suppressor pathway potentially involving the IL-6/STAT3 axis as a restricting factor in prostate cancer deficient in the tumour suppressor phosphatase and tensin homologue (PTEN) opened new avenues to currently available therapies.
RASSF6; the Putative Tumor Suppressor of the RASSF Family.
Hata et al., Tokyo, Japan. In Cancers (basel), 2014
RASSF6 binds MDM2 and regulates p53 expression.
Rb suppresses human cone-precursor-derived retinoblastoma tumours.
Cobrinik et al., New York City, United States. In Nature, 2014
Proliferation followed the induction of E2F-regulated genes, and depended on factors having strong expression in maturing cone precursors and crucial roles in retinoblastoma cell proliferation, including MYCN and MDM2.
USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses.
Sun et al., Houston, United States. In Nat Immunol, 2014
USP15 stabilized the E3 ubiquitin ligase MDM2, which in turn negatively regulated T cell activation by targeting the degradation of the transcription factor NFATc2.
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
Bonnefoi et al., Villejuif, France. In Lancet Oncol, 2014
117 (39%) of 297 patients with genomic tests available presented with rare genomic alterations (defined as occurring in less than 5% of the general population), including AKT1 mutations, and EGFR, MDM2, FGFR2, AKT2, IGF1R, and MET high-level amplifications.
Drugging the p53 pathway: understanding the route to clinical efficacy.
Lane et al., Singapore, Singapore. In Nat Rev Drug Discov, 2014
The first clinical results with inhibitors of MDM2, a negative regulator of p53, have shown efficacy but hint at on-target toxicities.
Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
Zhang et al., Amarillo, United States. In J Biol Chem, 2012
Transcription factor NFAT1 activates the mdm2 oncogene independent of p53.
Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Brüschweiler et al., Tallahassee, United States. In J Biol Chem, 2012
Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53.MDM2/MDMX interaction
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang et al., Beijing, China. In Acta Biochim Biophys Sin (shanghai), 2012
disruption of p53-MDM2 interaction by Nutlin-3a might reduce cell proliferation and promote apoptosis in osteosarcoma with MDM2 amplification and wt p53 status
Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
Zhang et al., Chapel Hill, United States. In Plos One, 2011
the role of Mdm2's RING domain in the control of p53
Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome.
Olalla Saad et al., Campinas, Brazil. In Neoplasma, 2011
MDM2 polymorphisms are not involved in myelodysplastic syndrome.
More papers using mdm2 antibodies
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels
Yamada Yoshihiko et al., In The Journal of Cell Biology, 1993
... p53, Akt, p-Akt, Smad1, and P-Smad1/5 were obtained from Cell Signaling Technology; Rb, P-NFATc1, and MDM2 were from Santa Cruz Biotechnology, Inc.; NFATc1 was from ...
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.
Sugden Bill, In PLoS Pathogens, 1993
... (BD Transduction Laboratory), mouse anti-Elongin B (BioLegend), mouse anti-GAPDH (Ambion), monoclonal mouse anti-p53 (Ab-6) (Merck), mouse anti-MDM2 (Ab-3) (Merck) and mouse anti-FLAG M2 ...
share on facebooktweetadd +1mail to friends